Cytomegalovirus (CMV) is a common viral pathogen in the transplant population and is
associated with significant morbidity and mortality. CMV prevention is paramount; however …

Cytomegalovirus (CMV) is a common infection encountered in immunocompromised
patients. It is associated with high morbidity and mortality, particularly in patients undergoing …

Letermovir is approved by the Food and Drug Administration for cytomegalovirus (CMV)
prophylaxis in CMV seropositive recipients of allogeneic stem cell transplantation (alloSCT) …

Letermovir is the first approved drug for cytomegalovirus (CMV) infection prophylaxis in adult
patients who are CMV positive undergoing allogeneic hematopoietic cell transplantation …

Cord blood transplantation (CBT) can be complicated by a high incidence of clinically
significant cytomegalovirus infection (csCMVi). We have investigated the efficacy of …

Abstract On November 7, 2017, the US Food and Drug Administration approved the use of
letermovir (LMV) for prophylaxis of cytomegalovirus (CMV) infection in adult CMV …

Reactivation of latent cytomegalovirus (CMV) is increased in recipients of allogeneic
hematopoietic cell transplantation (allo-HCT) with seropositive CMV using posttransplant …

Background There is scarce information on the natural kinetics of cytomegalovirus (CMV)
DNAemia and dynamics of CMV‐specific T‐cell reconstitution in allogeneic hematopoietic …

To explore the impact of letermovir (LET) prophylaxis on cytomegalovirus (CMV) reactivation
and resistance in both adult and paediatric umbilical cord blood transplantation (UCBT) …

In the absence of prophylactic therapy, cytomegalovirus (CMV) viremia is a common
complication following allogeneic hematopoietic cell transplantation (allo-HCT) and …